JP2022553652A5 - - Google Patents

Info

Publication number
JP2022553652A5
JP2022553652A5 JP2022521680A JP2022521680A JP2022553652A5 JP 2022553652 A5 JP2022553652 A5 JP 2022553652A5 JP 2022521680 A JP2022521680 A JP 2022521680A JP 2022521680 A JP2022521680 A JP 2022521680A JP 2022553652 A5 JP2022553652 A5 JP 2022553652A5
Authority
JP
Japan
Application number
JP2022521680A
Other languages
Japanese (ja)
Other versions
JP2022553652A (ja
JP7850068B2 (ja
JPWO2021074399A5 (https=
Filing date
Publication date
Priority claimed from EP19203549.1A external-priority patent/EP3808336A1/de
Application filed filed Critical
Publication of JP2022553652A publication Critical patent/JP2022553652A/ja
Publication of JP2022553652A5 publication Critical patent/JP2022553652A5/ja
Publication of JPWO2021074399A5 publication Critical patent/JPWO2021074399A5/ja
Priority to JP2025279962A priority Critical patent/JP2026034780A/ja
Application granted granted Critical
Publication of JP7850068B2 publication Critical patent/JP7850068B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022521680A 2019-10-16 2020-10-16 高親油性生理活性物質の放出制御製剤 Active JP7850068B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025279962A JP2026034780A (ja) 2019-10-16 2025-12-24 高親油性生理活性物質の放出制御製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19203549.1A EP3808336A1 (de) 2019-10-16 2019-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen
EP19203549.1 2019-10-16
PCT/EP2020/079244 WO2021074399A1 (de) 2019-10-16 2020-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025279962A Division JP2026034780A (ja) 2019-10-16 2025-12-24 高親油性生理活性物質の放出制御製剤

Publications (4)

Publication Number Publication Date
JP2022553652A JP2022553652A (ja) 2022-12-26
JP2022553652A5 true JP2022553652A5 (https=) 2023-10-19
JPWO2021074399A5 JPWO2021074399A5 (https=) 2023-10-19
JP7850068B2 JP7850068B2 (ja) 2026-04-22

Family

ID=68281165

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022521680A Active JP7850068B2 (ja) 2019-10-16 2020-10-16 高親油性生理活性物質の放出制御製剤
JP2025279962A Pending JP2026034780A (ja) 2019-10-16 2025-12-24 高親油性生理活性物質の放出制御製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025279962A Pending JP2026034780A (ja) 2019-10-16 2025-12-24 高親油性生理活性物質の放出制御製剤

Country Status (10)

Country Link
US (1) US20240148758A1 (https=)
EP (2) EP3808336A1 (https=)
JP (2) JP7850068B2 (https=)
CN (1) CN114929197A (https=)
AU (1) AU2020366134B2 (https=)
BR (1) BR112022006678A2 (https=)
CA (1) CA3157693A1 (https=)
IL (1) IL292019A (https=)
MX (1) MX2022004522A (https=)
WO (1) WO2021074399A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
SK287111B6 (sk) * 1998-08-27 2009-12-07 Pharmacia & Upjohn Ab Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
WO2008021394A2 (en) * 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
US20130338220A1 (en) * 2010-10-05 2013-12-19 Mark Tepper Compositions, dosages, and methods of using tetrahydrocannabinol derivatives
AU2014340709B2 (en) 2013-10-29 2019-07-04 Echo Pharmaceuticals B.V. Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
WO2018035030A1 (en) 2016-08-15 2018-02-22 Corr-Jensen Inc. Time release fat-soluble actives
EP3808341A1 (de) * 2019-10-16 2021-04-21 ADD Advanced Drug Delivery Technologies, Ltd. Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen

Similar Documents

Publication Publication Date Title
CN305528309S (https=)
CN306142896S (https=)
CN305586221S (https=)
CN305586491S (https=)
CN305586993S (https=)
CN305587990S (https=)
CN305588185S (https=)
CN305618998S (https=)
CN305634697S (https=)
CN305634949S (https=)
CN305640943S (https=)
CN305747547S (https=)
CN305756224S (https=)
CN305765087S (https=)
CN305766112S (https=)
CN305770227S (https=)
CN305770926S (https=)
CN305773028S (https=)
CN305774074S (https=)
CN305775128S (https=)
CN305777732S (https=)
CN305778899S (https=)
CN305781220S (https=)
CN305920866S (https=)
CN306045455S (https=)